Search

Your search keyword '"Ardizzone, M"' showing total 244 results

Search Constraints

Start Over You searched for: Author "Ardizzone, M" Remove constraint Author: "Ardizzone, M"
244 results on '"Ardizzone, M"'

Search Results

1. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count

4. Assessment of genetically modified maize MON 87419 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2017-140)

5. Efficacité de l’association de l’ETP individuelle et collective sur l’acquisition de compétences de sécurité des biothérapies sous-cutanées dans les RIC. Étude contrôlée, randomisée, multicentrique (ERIBIO)

6. Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study

7. Correction to: Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study (Updates in Surgery, (2021), 73, 2, (731-744), 10.1007/s13304-021-01010-w)

8. Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study

9. POS1223 DIFFERENT ANTI-SARS-CoV-2 VACCINE RESPONSE UNDER B- AND T-CELL TARGETED THERAPIES VERSUS ANTI-CYTOKINE THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES

11. Ce que nous apprennent nos HDJ sur la réponse vaccinale anti-SARS-CoV-2 différente sous traitements ciblant les lymphocytes B et T par rapport aux traitements anti-cytokiniques

14. Assessment of genetically modified maize MON 88017 × MON 810 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐017)

16. OP0282 RITUXIMAB ASSOCIATED WITH SEVERE COVID-19 AMONG PATIENTS WITH INFLAMMATORY ARTHRITIDES: A 1-YEAR MULTICENTER STUDY IN 1116 SUCCESSIVE PATIENTS RECEIVING BIOLOGIC AGENTS

17. Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit

18. Assessment of genetically modified oilseed rape GT73 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐002)

19. Assessment of genetically modified soybean A2704-12 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA-GMO-RX-009)

20. Statement complementing the EFSA Scientific Opinion on application (EFSA-GMO-NL-2009-75) for placing on the market of genetically modified oilseed rape Ms8 x Rf3 x GT73 and subcombinations; which have not been authorised previously (i.e. Ms8 x GT73 and Rf3 x GT73) independently of their origin; for food and feed uses; import and processing; with the exception of isolated seed protein for food; under Regulation (EC) No 1829/2003); taking into consideration additional information

21. Assessment of genetically modified maize MZIR098 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐DE‐2017‐142)

22. MANAGEMENT AND OUTCOME OF SEPTIC ARTHRITIS OF NATIVE JOINT: A NATIONWIDE SURVEY

23. Assessment of genetically modified soybean MON 87705 × MON 87708 × MON 89788, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2015‐126)

24. Assessment of genetically modified maize MON 88017 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐014)

25. Assessment of genetically modi¿ed oilseed rape MS11 for food and feed uses; import and processing; under Regulation (EC) No 1829/2003 (application EFSA-GMO-BE-2016-138)

26. Assessment of genetically modified soybean SYHT0H2 for food and feed uses, import and processing, under Regulation (EC) No 1829/2003 (application EFSA-GMO-DE- 2012-111)

27. Tocilizumab for treatment of severe covid-19 patients: Preliminary results from smatteo covid19 registry (smacore)

28. Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy

29. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count

33. Wild rats as urban detectives for latent sources of asbestos contamination

34. FRI0449 MANAGEMENT AND OUTCOME OF SEPTIC ARTHRITIS OF NATIVE JOINT: A NATIONWIDE SURVEY

35. Assessment of genetically modified soybean MON 87751 × MON 87701 × MON 87708 × MON 89788 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2016‐128)

36. Assessment of genetically modified maize MIR604 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐013)

37. Assessment of genetically modified maize MON 89034 for renewal authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐015)

38. Assessment of genetically modified maize MON 87427 × MON 89034 × MIR162 × MON 87411 and subcombinations, for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2017‐144)

39. Statement complementing the EFSA Scientific Opinion on application (EFSA‐GMO‐UK‐2006‐34) for authorisation of food and feed containing, consisting of and produced from genetically modified maize 3272

40. Assessment of genetically modified oilseed rape T45 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐012)

41. Assessment of genetically modified maize MON89034x1507xNK603xDAS-40278-9 and subcombinations independently of their origin for food and feed uses, import and processing, under Regulation (EC) No1829-2003 (application EFSA-GMO-NL-2013-112)

42. Assessment of genetically modified soybean MON 89788 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐011)

43. Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐010)

44. Assessment of genetically modified maize MZHG0JG for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA-GMO-DE-2016-133)

Catalog

Books, media, physical & digital resources